Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 3 Thrombocythemia, Essential 2 Philadelphia Chromosome 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Brain Neoplasms 2 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Leukemia 1 Glioma 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Gemcitabine 295 Fluorouracil 82 Oxaliplatin 81 130-nm albumin-bound paclitaxel 68 Capecitabine 60 Leucovorin 56 Albumin-Bound Paclitaxel 54 Radiotherapy 51 Irinotecan 44 Taxes 37 Cisplatin 36 Erlotinib Hydrochloride 34 Radiosurgery 33 pembrolizumab 29 Docetaxel 27 S 1 (combination) 26 Bevacizumab 23 folfirinox 22 Nivolumab 21 Magnetic Resonance Spectroscopy 17 Cyclophosphamide 17 Cetuximab 17 irinotecan sucrosofate 16 Radiation 16 Drug Therapy 15 Surgical Procedures, Operative 14 Specimen Handling 11 Biopsy 11 durvalumab 10 Paclitaxel 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Neoplasms × peginterferon alfa-2a × Clear all

NCT00178763 2011-03-03

FR-WB-TT

The University of Texas Health Science Center, Houston

Phase 2 Unknown

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡